

Author Index for 1987

Aalbers, C. 20:239, 22:127
Abrams, R. 20:57
Aceti, F. 20:207
Alessi, N.E. 20:275
Almay, B.G.L. 22:179
Amiri, Z. 21:221
Amsterdam, J.D. 20:325, 21:189
Angrist, B. 21:185
Ansseau, M. 22:193
Apelt, S. 22:303
Arató, M. 21:355
Arger, P. 21:189
Aryan, Z.S. 20:307
Asai, M. 21:49
Asnis, G. 20:79
Balon, R. 21:359, 22:37, 22:263
Barchas, J.D. 21:1, 22:21
Barksdale, C. 22:117
Bartkó, G. 22:221
Bartko, J.J. 20:165
Baumgartner, R. 20:33
Baxter, L.R., Jr. 21:237
Bellodi, L. 21:293
Benjamin, E. 22:257
Benkert, O. 20:177
Berchou, R. 21:359
Berenbaum, S.A. 20:57
Berg, L. 21:55
Berger, P.A. 20:47, 21:1, 22:21, 22:29
Berman, N. 20:1
Berman, S.R. 21:95
Berrettini, W.H. 22:141
Bigler, E.D. 22:91
Bochnik, H.J. 22:275
Boronow, J. 22:91
Borst, U. 22:331
Boulenger, J.-P. 21:247
Brambilla, F. 20:19
Breslau, N. 20:285
Brewerton, T.D. 21:213
Brochet, D.M. 21:267
Brody, D. 21:185
Brown, A. 22:261
Bruza, D. 22:261
Burns, E.M. 20:165, 22:229
Burrows, G.D. 22:43
Butters, N. 21:357
Byron, J.P., Jr. 20:261
Calderon, M. 20:33
Calil, H.M. 21:337
Campeas, R. 22:89
Candolfi, C. 20:19
Carpenter, W.T., Jr. 22:319
Carstens, M.E. 20:239, 22:127
Casper, R.C. 20:249
Cavagnini, F. 20:19
Cazzullo, C.L. 21:293
Cerfontaine, J.-L. 22:193
Chalton, D.O. 20:239, 22:127
Chamberlain, K.G. 20:199
Channabasavanna, S.M. 21:349
Charney, D.S. 21:33
Cherek, D.R. 21:257
Chrousos, G.P. 20:229
Climko, R. 20:261
Coccaro, E.F. 22:257
Codd, E.E. 22:61
Coffman, J.A. 22:229
Cohen, B.M. 20:107, 20:299
Cohen, M.R. 21:43
Cohen, R. 22:331
Cohn, B.S. 21:205
Cole, J.O. 20:143, 20:155
Comess, K.A. 20:13
Cooper, T.B. 20:313
Coromilas, J. 22:341
Coryell, W. 20:265
Coulter, M.E. 22:149
Cowley, D.S. 21:169
Csernansky, J.G. 20:47
Dackis, C.A. 20:261
Dager, S.R. 20:13, 21:169
Davidson, M. 20:307
Davies, B.M. 22:213
Davies, M. 22:341
Davis, G.C. 20:285
Davis, J.M. 20:165, 22:265
Davis, K.L. 20:307, 22:257
Dawson, G. 22:117
Delis, D.C. 21:357
DeLisi, L.E. 20:69
Demeter, E. 21:355
Demisch, L. 22:275
De Ruyter, M. 21:323
de Villiers, A.S. 22:127
Dillon, D.J. 20:97, 21:205
Dilsaver, S.C. 20:275
di Rosa, M. 21:293
Dixon, K.N. 20:189
Dobben, G.D. 20:165
Doran, A.R. 21:23
Dose, M. 22:303
Drinka, P.J. 21:199

Droba, M. 20:325
 Dugger, D. 21:123
 Dunner, D.L. 21:13, 21:169
 Dupont, R. M. 21:357
 Dysken, M. 20:165
 Ebstein, R.P. 21:221
 Edell, W.S. 20:129
 Emrich, H.M. 22:303
 Engelbrecht, A.H. 20:239
 Erlenmeyer-Kimling, L. 22:159
 Fairbanks, L. 21:237
 Falus, A. 21:355
 Faull, K.F. 21:1, 22:21
 Fiume, S. 20:207
 Foa, E.B. 21:123
 Foreman, P.J. 22:69
 Fraioli, F. 20:207
 Frajese, G. 20:207
 Franck, G. 22:193
 Frazer, A. 20:1
 French, M.A. 20:199
 Frick, K. 20:117
 Friedhoff, A.J. 21:185
 Fuentenebro, F. 22:283
 Fujita, H. 21:285, 22:81
 Fulgham, J.R. 21:359
 Fyer, A.J. 20:97, 21:23, 21:205, 22:341
 Gagiano, C.A. 20:239, 22:127
 Galderisi, S. 21:137
 Gambini, O. 21:293
 Garbutt, J.C. 21:307
 Garnett, D. 21:89
 Garvey, M.J. 20:183
 Gebhart, P. 22:275
 Geenen, V. 22:193
 Gelenberg, A.J. 20:107
 George, D.T. 21:213
 Georgi, K. 22:275
 Gerbaldo, H. 22:275
 Gershon, E.S. 20:69
 Gillin, J.C. 20:181, 21:357
 Giordani, A.B. 20:307
 Glenn, M. 21:307
 Glover, V. 22:111
 Gold, M.S. 20:261
 Gold, P.W. 20:229
 Goldin, L.R. 20:69
 Goldstein, S. 20:79
 Goodman, S.I. 22:291
 Gorman, J.M. 20:97, 21:23, 21:205, 22:371
 Gottesman, I.I. 22:159
 Grabowski, J. 22:261
 Graziosi, S. 20:207
 Griez, E.J.L. 20:87
 Gross, H.S. 22:69
 Grossman, A. 22:207
 Guthrie, S. 21:161
 Gutman, R. 21:43
 Guze, B.H. 21:237
 Halbreich, U. 20:79
 Hama, Y. 21:285
 Hanin, I. 22:49
 Harrison, W. 21:9
 Heinrichs, D.W. 22:319
 Heninger, G.R. 21:33
 Herzeg, I. 22:221
 Hesselink, J.R. 21:357
 Himmelhoch, J.M. 22:49
 Hobin, P. 21:323
 Hoch, C.C. 21:95, 21:111
 Hollander, E. 22:89
 Hollifield, M. 21:313
 Holsboer, F. 20:83, 20:177
 Houck, P.A. 21:95
 Hsiao, J.K. 22:69
 Huggins, T. 22:11
 Hyde, T.S. 21:169
 Innis, R.B. 21:33
 Invitti, C. 20:19
 Ito, M. 21:285, 22:81
 Irwin, M.R. 20:181, 22:283
 Ishii, T. 21:285, 22:81
 Jacobsen, F.M. 22:1
 James, S.P. 21:89
 Janicak, P.G. 22:265
 Javad, J.I. 20:249
 Jernigan, T.L. 21:357
 Jimerson, D.C. 21:213
 Joffe, R.T. 21:71
 Jordan, R.C. 21:63
 Judd, F.K. 22:43
 Kaku, H. 21:229
 Kalin, N.H. 22:117
 Kanba, S. 21:49
 Kang, B.J. 20:79
 Kärkkäinen, J. 21:151
 Kartakis, D. 20:221
 Kathol, M.H. 22:229
 Katon, W.J. 21:313
 Kaufmann, C.A. 20:337
 Kelly, T.H. 21:257
 Kemali, D. 21:137
 Kempler, S. 22:311

Khan, A. 20:13
 Khanna, S. 21:349
 Kimber, N.M. 22:43
 King, R.J. 21:1, 22:29
 Kishimoto, H. 21:285, 22:81
 Kitamura, T. 21:49
 Klar, H. 22:257
 Klein, D.F. 20:97, 21:23, 21:205, 22:341
 Kleinman, J.E. 22:291
 Knopf, S. 22:49
 Knowles, J.B. 22:149
 Korpi, E.R. 20:337, 22:291
 Koslow, S.H. 20:1
 Kozak, M.J. 21:123
 Kruckeberg, T.W. 22:229
 Kupfer, D.J. 21:95, 21:111
 Kuwahara, H. 21:285, 22:81
 Laatikainen, T. 21:151
 Lacoste, V. 21:181
 Lajtha, A. 20:313
 Lampertico, M. 20:19
 Langlais, P.J. 20:143, 20:155
 Legros, J.-J. 22:193
 Lerbinger, J.E. 20:143, 20:155
 Lerer, B. 21:221
 Levin, A.P. 21:23
 Levy, A.B. 20:189
 Liebowitz, M.R. 20:97, 21:23, 21:205,
 22:89, 22:341
 Linnoila, M. 20:229, 21:161
 Loosen, P.T. 21:307
 Lousberg, H. 20:87
 Lykouras, L. 21:277
 Lynch, J.J. 22:69
 Macciardi, F. 21:293
 MacLean, A. 22:149
 Maddock, R.J. 22:29
 Maes, M. 21:323
 Maggioni, M. 20:19
 Magnani, A. 20:207
 McGuire, K.P. 22:213
 Magyar, K. 21:355
 Maislin, G. 20:325
 Maj, M. 21:137
 Malliaras, D. 21:277
 Mallinger, A.G. 22:49
 Mandal, M.K. 20:317
 Marangos, P.J. 21:247
 Marder, L.R. 20:215
 Marder, S.R. 22:283
 Marinelli, D.L. 21:189
 Markianos, M. 20:221
 Markowitz, J.S. 21:9
 Marnela, K.M. 20:337
 Martin, J.V. 21:89
 Martin, P. 21:267
 Masuda, Y. 21:49
 Matsushita, M. 21:285, 22:81
 Matussek, N. 21:85
 Maylath, E. 22:221
 Mazzuotta, J.C. 21:237
 McAllister, D.A. 21:63
 McAmis, W. 21:43
 McCauley, R.B. 22:37
 McGrath, P.J. 21:9
 McIntyre, I.M. 22:43
 Melia, E. 20:207
 Meltzer, H.Y. 22:99
 Mendelson, W.B. 21:89
 Meyer, J.S. 20:129
 Miller, M.M. 20:143
 Milton, J. 21:89
 Mintz, M. 22:311
 Miyauchi, T. 21:285
 Mohs, R.C. 20:307
 Moldin, S.O. 22:159
 Morris, J.C. 21:55
 Moscovitch, D. 21:221
 Moses, J.A., Jr. 22:29
 Müller, E.E. 20:19
 Müller-Oerlinghausen, B. 20:117
 Murchison, A. 22:29
 Mykytyn, V.V. 20:307
 Nakagawara, M. 21:85, 21:229
 Nasrallah, H.A. 21:303, 22:229
 Naukkarinen, H. 21:151
 Nemes, Z.C. 20:313
 Nerozzi, D. 20:207
 Nomura, Y. 21:285
 Norman, T.R. 20:199, 22:43
 Nurnberger, J.I., Jr. 22:141
 Ohno, S. 21:285, 22:81
 Orsulak, P.J. 20:183
 Oxenkrug, G.F. 22:37
 Palkovits, M. 21:355
 Pandey, G.N. 22:265
 Panerai, A.E. 20:19
 Papart, P. 22:193
 Patlak, C.S. 20:165
 Paul, S.M. 21:23
 Peabody, C.A. 21:1, 22:21
 Perel, J.M. 21:111
 Perri, M.G. 21:63
 Pettigrew, K.D. 20:165
 Phelps, M.E. 21:237

Pickar, D. 20:229, 21:161, 22:91
 Pirozzi, R. 21:137
 Platt, S. 20:307
 Plutchik, R. 22:243
 Pohl, R. 21:359, 22:37, 22:263
 Post, R.M. 21:71, 22:11
 Prabucki, K. 20:285
 Prasad, A. 22:111
 Quitkin, F.M. 21:9
 Rabkin, J.G. 21:9
 Rai, A. 20:317
 Rainey, J.M. 21:359, 22:37
 Raisys, V. 20:13
 Rampling, R.P. 22:111
 Rauscher, F.P. 21:63
 Raz, N. 22:91
 Raz, S. 22:91
 Regier, D.A. 20:165
 Reynolds, C.F. III 21:95, 21:111
 Rimon, R. 21:151
 Robbins, D.R. 20:275
 Robinson, D. 21:257
 Rosenberg, S. 20:57
 Rosenthal, N.E. 22:1
 Roth, W.T. 22:29
 Rothschild, A.J. 20:143, 20:155
 Rotrosen, J. 21:185
 Rotter, A. 22:1
 Roy, A. 20:229, 21:161
 Roy-Byrne, P.P. 21:71
 Rubenstein, K. 22:257
 Rubin, E.H. 21:55
 Rubinow, D.R. 22:11
 Russell, V.A. 20:239, 22:127
 Ryan, J. 20:79
 Sacchetti, E. 21:293
 Sack, D.A. 21:89
 Sakellariou, G. 20:221
 Salem, N., Jr. 21:247
 Sali, L. 20:19
 Salminen, K. 21:151
 Salvati, A. 21:137
 Sandler, M. 22:111
 Sato, C. 21:285
 Sattin, A. 21:63
 Schatzberg, A.F. 20:143, 20:155
 Schildkraut, J.J. 20:155
 Schlemmer, R.F., Jr. 20:249
 Schmidt, H. 20:189
 Schweitzer, J. 21:185
 Secunda, S. 20:1
 Selin, C.E. 21:237
 Sershen, H. 20:313
 Sharpless, N. 20:79
 Shelton, S. 22:117
 Sherwood, P. 22:263
 Shima, S. 21:49
 Shimogawa, S. 21:229
 Siever, L.J. 22:257
 Sigal, M. 22:311
 Simmons-Alling, S. 22:141
 Simon, P. 21:267
 Sitaram, N. 22:261
 Skwerer, R.G. 22:1
 Smeraldi, E. 21:293
 Smith, R.C. 20:33
 Soubrie, P. 21:267
 Spoor, J. 21:151
 Stack, J.A. 21:95, 21:111
 Starace, F. 21:137
 Stefanis, C. 21:277
 Steiger, A. 20:177
 Steinberg, J.L. 21:257
 Steinman, R. 22:341
 Steketee, G. 21:123
 Stenman, U.-H. 21:151
 Stewart, J.W. 21:9
 Stiglitz, R.-D. 20:117
 Storandt, M. 21:55
 Sunderland, T. 20:299
 Surridge-David, M. 22:149
 Suy, E. 21:323
 Swann, A.C. 20:1
 Sweeney, D.R. 20:261
 Takahashi, R. 21:229
 Takazu, O. 21:285, 22:81
 Taljaard, J.J.F. 20:239, 22:127
 Tariot, P. 22:117
 Taylor, M.A. 20:57
 Tekes, K. 21:355
 Thase, M.E. 22:49
 Thiemann, S. 20:47
 Thienemann, M. 22:117
 Tiller, J.W.G. 22:213
 Timsit-Berthier, M. 22:193
 Tollefson, G.D. 20:183
 Tomer, R. 22:311
 Tóthfalusi, L. 21:355
 Tsichlakis, N. 20:221
 Tsukomo, T. 21:49
 Turkheimer, E. 22:91
 Turner, T.H. 22:207
 Uhde, T.W. 21:71, 21:247, 22:11
 Ulrich, G. 20:117
 Ur, E. 22:207


Valente, A. 21:137
van den Hout, M.A. 20:87
van der Molen, G.M. 20:87
van Praag, H.M. 22:243
Vassilopoulos, D. 21:277
Veith, R.C. 21:313
Villacres, E.C. 21:313
Vita, A. 21:293
Vocks, S.K. 21:199
Volavka, J. 20:313
von Frencell, R. 22:193
von Knorring, L. 22:179
Voulgari, A. 21:277

Wagman, A.M.I. 22:319
Wagner, R. 21:89
Walker, R.F. 22:61
Warner, M.D. 22:21
Watanabe, A. 21:229
Wehr, T.A. 21:89
Weiler, S. 22:117
Weinberger, D.R. 20:337, 22:91
Wetterberg, L. 22:179

Whiteford, H.A. 21:1, 22:21
Wiedemann, K. 20:83
Wilcox, J.A. 21:303
Wilkinson, C.W. 21:313
Winokur, A. 20:325, 21:189
Wirz-Justice, A. 21:181
Witzke, W. 21:85
Wolfe, N. 20:107
Woods, D.J. 20:215
Wyatt, R.J. 22:291

Yamaguchi, T. 22:81
Yehuda, R. 20:129
Yeragani, V.K. 21:359, 22:37, 22:263
Yokoi, S. 21:285, 22:81
Yoshimoto, S. 21:229
Yuwiler, A. 22:283

Zeevi, S. 21:221
Zimmer, B. 21:111
Zimmerman, M. 20:265
Zureick, J.L. 22:99
Zwicker, A.P. 21:337



Subject Index for 1987

Adenosine
 caffeine in plasma, anxiety, 21:247

Adenylate cyclase
 lithium, platelet, 21:221

α_2 -Adrenoceptor
 affective disorder, platelet, 22:127
 affective illness, yohimbine in platelets, 20:107
 panic disorder, rauwolscine binding, 22:43

β -Adrenoceptor
 affective disorder, lymphocyte binding, 20:239
 affective disorder, platelet, 22:127
 leukocyte membrane, cyanopindolol, 22:265
 schizophrenia, affective disorders, 22:265

Adrenocorticotrophic hormone
 cortisol, affective illness, 20:325, 22:117
 lactate induced panic, 21:23

Affective disorder
 adrenal gland volume, computed tomography, 21:189
 α_2 -adrenoceptor, platelets, 20:107, 22:127
 β -adrenoceptor binding, dexamethasone suppression test, 22:265
 β -adrenoceptor binding, severity, 20:239, 22:127
 adrenocorticotrophic hormone, dexamethasone suppression, 20:235, 22:117
 amino acids in serum, dexamethasone suppression test, 21:323
 apomorphine, growth hormone, 22:193
 arachidonic acid, platelet membrane phospholipid incorporation, 22:275
 arecoline infusion, sleep, 22:261
 bipolar disorder, growth hormone releasing factor, 22:141
 bipolar disorder, growth hormone response to clonidine, 22:193
 bipolar disorder, sodium transport, 22:49
 bipolar/unipolar, Minnesota Multiphasic Personality Inventory, 22:159
 bipolar/unipolar, norepinephrine, 21:161
 bipolar/unipolar, panic attack incidence, 20:183
 bipolar/unipolar, positron emission tomography, 22:81
 blood pressure, clonidine and apomorphine response, 22:193

Affective disorder (cont.)
 blood pressure, endogenous subtype, 21:85
 calcium in serum, anxiety, 22:29
 carbamazepine, family history, 21:71
 carbamazepine, sleep deprivation, 22:11
 catecholamines, dexamethasone, 20:143, 22:21, 22:127
 circadian rhythm, plasma 3-methoxy-4-hydroxyphenylglycol, 20:79
 clonidine, growth hormone, 22:193
 corticotropin releasing hormone, affective illness, 20:229
 cortisol, catecholamines, 20:143, 22:21, 22:127
 cortisol, electroconvulsive therapy and naloxone, 22:207
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127
 cortisol, naloxone effect, 22:207
 cortisol response to adrenocorticotrophic hormone, 20:235, 22:117
 cortisol, serum amino acids, 21:323
 delusional depression, family study, 21:277
 dementia, antidepressants, 21:111
 depression assessment, comparison of five self-report scales, 22:243
 depression, Plutchik-van Praag self-report scale, 22:243
 dexamethasone, cortisol, 20:143, 22:21, 22:117
 dexamethasone, β -endorphin, 21:151
 dexamethasone in plasma, cortisol suppression, 20:83
 dexamethasone suppression test, β -adrenoceptor binding, 22:P\$
 dexamethasone suppression test, adrenocorticotrophic hormone, 22:117
 dexamethasone suppression test, melancholic subgroups, 20:235
 dexamethasone suppression test, norepinephrine, 21:161
 dexamethasone suppression test, serum amino acids, 21:323
 dexamethasone suppression, thyroid stimulating hormone, 22:21, 22:127
 dexamethasone suppression, urinary catecholamines, 20:229
 dopamine in plasma, psychotic depression, 20:143

Affective disorder (cont.)

- electroconvulsive therapy, carbamazepine, 22:11
- electroconvulsive therapy frequency, 21:63
- electroconvulsive therapy, naloxone neuroendocrine effect, 22:207
- electroconvulsive therapy, thyroid-stimulating hormone, 20:207
- emotional blunting, factor analytic study, 20:57
- β -endorphin, dexamethasone, 21:151
- familial subtypes, 3-methoxy-4-hydroxyphenylglycol, 22:117
- family history, carbamazepine response, 21:71
- fenfluramine response, prolactin 22:257
- frontal lobe, positron emission tomography, 22:81
- generalized anxiety disorder, mothers' illness, 20:285
- glucose in serum, anxiety, 22:29
- growth hormone, clonidine response, 22:193
- growth hormone, electroconvulsive therapy and naloxone, 22:207
- growth hormone releasing factor, lithium, 22:141
- head trauma, bipolar/depressive 21:303
- homovanillic acid, thyroid-stimulating hormone, 22:21
- hyperventilation, serum phosphate, 22:29
- hypothyroidism, depressive symptoms, 21:199
- imipramine binding, platelet, 21:33
- immune cell function, natural killer cell activity, 20:181
- light therapy, mood effect, 22:1
- lithium distribution, mania, 20:1
- lithium effect, sodium transport, 22:49
- lithium, growth hormone releasing factor, 22:141
- magnetic resonance imaging, bipolars, 21:357
- mania, growth hormone response to clonidine and apomorphine, 22:193
- membrane potential, lithium effect, 22:49
- 3-methoxy-4-hydroxyphenylglycol, circadian rhythm, 20:79
- 3-methoxy-4-hydroxyphenylglycol, panic attacks, 20:183
- 3-methoxy-4-hydroxyphenylglycol, thyroid-stimulating hormone, 22:21, 22:127

Affective disorder (cont.)

- Minnesota Multiphasic Personality Inventory, 22:159
- monoamine metabolites, red blood cell/lithium ratio, 20:1
- monoamine oxidase inhibitors, social behavior, 22:89
- naloxone, electroconvulsive therapy, 22:207
- norepinephrine, cold challenge, 21:161
- norepinephrine in plasma, cortisol, 22:117
- opioids, electroconvulsive therapy, 22:207
- panic disorders, adolescents, 20:275
- phosphate serum levels, anxiety, 22:29
- phospholipids, arachidonic acid incorporation, 22:275
- placebo response, antidepressants, 21:9
- positron emission tomography, bipolar/unipolar, 22:81
- prolactin, electroconvulsive therapy and naloxone, 22:207
- prolactin response, fenfluramine, 22:257
- psychotic depression, plasma dopamine, 20:143
- secondary depression, thyroid-stimulating hormone, 22:21
- self-report scales, development and methodology, 22:243
- serotonin reuptake inhibitors, fenfluramine, 22:257
- severity, β -adrenoceptor binding, 20:239
- severity, dopamine in plasma, 20:143
- severity, rapid eye movement sleep, 20:189
- severity, thyroid-stimulating hormone, 22:21
- sleep, arecoline infusion, 22:261
- sleep deprivation, carbamazepine, 22:11
- sleep deprivation, older endogenous depression, 21:95
- sleep, frequency analysis of electroencephalogram, 21:89
- sleep variables, polysomnography 20:189
- sodium transport, lithium effect, 22:49
- suicidal thoughts, 5-hydroxy-indoleacetic acid, 21:1
- suicide, delusional depression, 21:277
- thyroid-stimulating hormone, depressive symptoms, 21:199
- thyroid-stimulating hormone, electroconvulsive therapy, 20:207
- thyroid-stimulating hormone, 3-methoxy-4-hydroxyphenylglycol, 22:21
- Age
- α_2 -adrenoceptors in platelets, affective illness 20:107

Age (cont.)

- anxiety, caffeine in plasma, 21:247
- cortisol, affective illness, 20:143, 20:155
- dopamine in plasma, affective illness, 20:143
- dopamine- β -hydroxylase, 20:221
- melatonin, chronic pain, 22:179

Aggressive behavior

- amphetamine, laboratory response, 21:257

Alcoholism

- perceptual aberration scale, monoamine oxidase, 20:129
- reaction time, evoked potentials, 22:85
- thyroid-stimulating hormone, secondary depression, 22:21

Alzheimer's dementia

- antidepressant treatment, 21:111
- personality change, factor structure, 21:55

Amino acids

- brains post-mortem, schizophrenia, 22:291
- dexamethasone suppression test, affective disorder, 21:323
- schizophrenia, levels in cerebrospinal fluid, 20:337

Amphetamine

- aggressive behavior, button press response, 21:257
- psychosis induction, 5-hydroxy-tryptophan, 22:283

Anorexia nervosa

- clonidine, growth hormone response, 20:19
- clonidine treatment, 3-methoxy-4-hydroxyphenylglycol, 20:249
- β -endorphin, desmethylimipramine response, 20:19
- rapid eye movement sleep, concurrent depression, 20:189

Antidepressants

- carbamazepine response, sleep deprivation and electroconvulsive therapy, 22:11
- dementia treatment in elderly, 21:111
- lactate panic, hyperventilation 21:205
- monoamine oxidase inhibitors, social behavior, 22:89
- placebo response, 21:9
- sleep deprivation, prolactin and growth hormone, 21:337
- triiodothyronine potentiation, learned helplessness, 21:267

Apomorphine

- growth hormone response, affective disorder, 22:193

Arachidonic acid

- membrane phospholipids, schizophrenia, 22:275

Arecoline

- rapid eye movement sleep, affective illness, 22:261

Attention

- electroencephalogram, lithium, 20:117
- negative symptoms, schizophrenia, 20:47

Blood pressure

- anorexia nervosa, clonidine, 20:19
- clonidine, anorexia nervosa, 20:249
- clonidine and apomorphine response, affective disorder, 22:193
- endogenous/nonendogenous diagnosis, 21:85
- lactate infusion, bulimia, 21:213
- lactate infusion, panic disorder, 21:169, 22:263
- mitral valve prolapse, panic disorder, 20:13
- panic disorder, plasma norepinephrine, 21:313
- schizophrenia, speaking, 22:69

Blood-brain barrier

- dynamic computed tomography, schizophrenia, 22:229

Borderline personality disorder

- prolactin, cortisol and T_3 , 21:307
- thyroid-stimulating hormone, haloperidol treatment, 21:307

Brain structure

- magnetic resonance imaging, schizophrenia, 20:33

Brofaremine

- rapid eye movement sleep, 20:177

Bromocriptine

- cocaine craving reversal, 20:261

Bulimia. See also Anorexia nervosa

- lactate induced panic, 21:213
- sleep recording, depression type, 20:189

Caffeine

- adenosine in plasma, anxiety, 21:247

Calcium

- affective disorder, serum levels, 22:29

Cancer

- monoamine oxidase in platelets, depression, 22:111

Carbamazepine

- mania response, family history, 21:71
- response rate compared to sleep deprivation, 22:11

Carbamazepine
schizophrenia, clinical response, 22:D\$

Carbidopa
homovanillic acid, lack of effect, 21:185

Carbon dioxide
panic disorder, inhalation, 20:87

Catecholamines
corticotropin-releasing hormone,
affective disorder, 20:229
depression severity, cerebrospinal fluid
levels, 21:1
dexamethasone, affective illness, 20:143
growth hormone response to clonidine
and apomorphine, 22:193
lithium treatment, red blood cell ratio,
20:1
monoamine oxidase, affective symptoms,
20:155
panic disorder, mitral valve prolapse, 20:13

Childhood disorders
generalized anxiety disorder, over-
anxious disorder, 20:285
panic disorder, concurrent depression,
20:275

Circadian rhythms
light therapy, mood change, 22:1
3-methoxy-4-hydroxyphenylglycol,
affective illness, 20:79
sleep phase shift, mood in normals,
22:149

Circannual rhythm
diurnal mood variation, 21:181
imipramine binding, affective disorder,
21:33
light therapy, seasonal affective disorder,
22:1
personality dimensions, 21:181
placebo response, antidepressants, 21:9

Clonidine
anorexia nervosa, growth hormone and
desmethylimipramine, 20:19
anorexia nervosa, 3-methoxy-4-hydroxy-
phenylglycol, 20:249
growth hormone response, affective
disorder, 22:193

Cocaine
bromocriptine reverses craving, 20:261

Computed tomography
adrenal gland volume, 21:189
blood-brain barrier, schizophrenia,
22:229
contrast material time-density curves,
schizophrenia, 20:165
schizophrenia, third ventricle enlarge-
ment, 21:49

Computed tomography (cont.)
ventricular size, methodological review,
22:91

Corticotropin releasing hormone
norepinephrine, affective disorder, 20:229

Cortisol
 β -adrenoceptor binding, schizophrenia and
affective disorder, 22:265
adrenocorticotrophic hormone effect,
affective illness, 20:235, 22:117
affective illness, dexamethasone, 20:143,
20:155
amino acids in serum, affective illness,
21:323
anorexia nervosa, clonidine and desmethyl-
imipramine, 20:19
borderline personality disorder, 21:307
 β -endorphin, dexamethasone, 21:151
lactate induced panic, 21:23
monoamine oxidase in platelet, 20:155
naloxone and electroconvulsive therapy,
22:207
norepinephrine, affective illness, 22:127

Cyanopindolol
leukocyte membrane binding, affective
disorder and schizophrenia, 22:265

Cyclic adenosine monophosphate
lithium adenylate cyclase in platelet, 21:221

Dementia
antidepressant treatment in elderly, 21:111

Desipramine
anorexia nervosa, weight, 20:19
cortisol, clonidine, 20:19
growth hormone, β -endorphin, 20:19
sleep deprivation, prolactin and growth
hormone, 21:337

Dexamethasone
adrenocorticotrophic hormone effect,
cortisol, 20:235
cortisol suppression, plasma level, 20:83

Dexamethasone suppression test
 β -adrenoceptor binding, affective disorder,
20:239, 22:265
 β -adrenoceptor binding, schizophrenia,
22:265
adrenocorticotrophic hormone, affective
illness, 22:117
amino acids in serum, affective disorder,
21:323
catecholamines in plasma, psychotic
depression, 20:143
corticotropin-releasing hormone,
norepinephrine, 20:229
cortisol, 3-methoxy-4-hydroxyphenylglycol,
22:127

Dexamethasone suppression test (cont.)

- β -endorphin and β -lipotropin, cortisol,** 21:151
- family history of affective illness,** 20:265
- norepinephrine, cold challenge,** 21:161
- thyroid-stimulating hormone, affective illness,** 22:21

Diagnosis

- Diagnostic Inventory Schedule for Children,** 20:285
- generalized anxiety disorder, validity,** 20:285
- Minnesota Multiphasic Personality Inventory, diagnostic validation,** 22:159
- panic disorder and concurrent depression in adolescents,** 20:275

Dihydroalprenolol

- lymphocyte binding, affective disorder,** 20:239

Dopamine

- affectionate illness, dexamethasone,** 20:143, 20:155
- Dopamine- β -hydroxylase schizophrenia, family study,** 20:221

Electroconvulsive therapy

- carbamazepine, sleep deprivation,** 22:11
- dementia,** 21:111
- naloxone, growth hormone and prolactin,** 22:207
- prolactin and thyroid-stimulating hormone,** 20:207
- treatment frequency,** 21:63

Electroencephalogram

- frequency analysis, sleep,** 21:89
- lithium, normal controls,** 20:117
- sleep, affective illness,** 21:89
- ventricular enlargement, frequency analysis in schizophrenia,** 21:137

β -Endorphin

- anorexia nervosa, clonidine,** 20:19

Epinephrine

- affectionate illness, dexamethasone,** 20:143, 20:155
- anxiety ratings, panic disorder,** 21:313

Evoked potentials

- contingent negative variation, schizophrenia and alcoholism,** 22:331
- neuroleptic side effects, hemispheric asymmetry,** 22:311

Eye movements

- lateralization, schizophrenia,** 20:215
- smooth pursuit, schizophrenia,** 21:293

Fenfluramine

- prolactin response, affective disorder,** 22:257

Frontal lobe

- amino acids, post-mortem brain in schizophrenia,** 22:291
- blood-brain barrier permeability, hypofrontal pattern,** 22:229
- glucose metabolic rate, affective disorder,** 22:81

Generalized anxiety disorder

- diagnostic validity, family study,** 20:285

Genetics

- delusional depression, multifactorial inheritance,** 21:277
- dexamethasone suppression, family history of affective illness,** 20:265
- dopamine- β -hydroxylase, schizophrenia, families,** 20:221
- generalized anxiety disorder, mother's illness,** 20:285
- human leukocyte antigens, schizophrenia,** 20:69
- 3-methoxy-4-hydroxyphenylglycol, familial subtypes of affective illness,** 22:117

Glucose

- phosphate serum level, affective illness,** 22:29
- positron emission tomography, affective disorder,** 22:81
- positron emission tomography, schizophrenia,** 21:285
- positron emission tomography, sex differences in metabolic rate,** 21:237

Growth hormone

- anorexia nervosa, clonidine and desmethyl-imipramine,** 20:19
- clonidine and apomorphine response, affective disorder,** 22:193
- naloxone and electroconvulsive therapy,** 22:207
- sleep deprivation, desimipramine treatment,** 21:337

Growth hormone releasing factor

- bipolar affective disorder, lithium effect,** 22:141

Heart rate

- clonidine, anorexia nervosa,** 20:249
- lactate infusion, panic disorder,** 22:341
- mitral valve prolapse, panic disorder,** 20:13
- panic disorder, plasma norepinephrine,** 21:313
- schizophrenia, speaking,** 22:69

Heart rate (cont.)
 sleep infusion of arecoline, affective illness, 22:261

Hemispheric asymmetry (see Laterality)

Homovanillic acid
 carbidopa effect, normal controls, 21:185
 depression, cerebrospinal fluid level, 21:1
 diet and physical activity, 20:307
 lithium distribution, mania, 20:1
 smoking, normal controls, 20:307
 thyroid stimulating hormone, affective illness, 22:21

Human leukocyte antigens
 schizophrenia, chromosome 6, 20:69

5-Hydroxyindoleacetic acid
 brains of suicides, 21:355
 depression, cerebrospinal fluid level, 21:1
 lithium distribution, mania, 20:1

5-Hydroxytryptamine
 brains of suicides, 21:355

5-Hydroxytryptophan
 amphetamine induced psychosis, schizophrenia, 22:283

Imipramine
 obsessive-compulsive disorder treatment, 21:123

Imipramine binding
 affective illness and panic disorder, 21:33
 brains of suicides, platelet binding, 21:355
 circannual variation, 21:33

Immune function
 affective illness, natural killer cells, 20:181

Isoproterenol
 blood pressure, panic disorder, 22:263

Lactate
 adrenocorticotrophic hormone, cortisol, 21:23
 antidepressants, panic, 21:205
 blood pressure, panic disorder, 22:263
 bulimia, anxiety, 21:213
 gravity feed administration, 21:359
 heart rate, panic disorder, 22:341
 panic attacks, baseline blood pressure, 21:169
 panic disorder, agoraphobia, 20:97

Laterality
 brains of suicides, serotonergic function, 21:355
 clockwise circling, schizophrenia, 20:215
 evoked potentials, neuroleptic side effects, 22:311

Learned helplessness
 triiodothyronine, antidepressant interaction, 21:267

Life events
 schizophrenia, relapse off medication, 22:221

Light
 treatment, depression change, 22:1

β -lipotropin
 dexamethasone, cortisol, 21:151

Lithium
 adenylate cyclase, platelet, 21:221
 electroencephalogram, normals, 20:117
 growth hormone releasing factor, bipolars, 22:141
 neuroleptic levels in brain and plasma, 20:313

Lithium (cont.)
 red blood cell ratio, monoamine metabolites, 20:1
 sodium transport, red blood cell, 22:49

Magnetic resonance imaging
 bipolar affective illness, subcortical signal hyperintensities, 21:357
 schizophrenia, ventricular size and image intensity, 20:33

Melatonin
 pain syndromes, depressive symptoms, 22:179

Membrane transport
 sodium transport, bipolar affective disorder, 22:49

Memory
 electroconvulsive therapy, 21:63

Melanophrine
 lithium distribution, mania, 20:1

3-Methoxy-4-hydroxyphenylglycol
 anorexia nervosa, clonidine treatment, 20:249

circadian rhythm, affective illness, 20:79
 corticotropin-releasing hormone, dexamethasone suppression test, 20:229
 cortisol, thyroid stimulating hormone, 22:127

depression, cerebrospinal fluid level, 21:1
 lithium distribution, mania, 20:1

Mitral valve prolapse
 panic disorder, panic disorder, 20:13

panic attacks, depressed patients, 20:183
 red blood cell/lithium ratio, mania, 20:1

thyroid-stimulating hormone, affective illness, 22:21

Mitral valve prolapse
 panic disorder, catecholamines, 20:13

Moclobemide
 tyramine-pressor response, clinical response, 22:213

Monoamine oxidase
 cancer, depression, 22:111
Hamilton Rating Scale for Depression,
 items, 20:155
mitral valve prolapse, panic disorder,
 20:13
panic disorder, platelets, 22:37
paranoia, schizophrenia, 22:99
psychosis proneness, college students,
 20:129
psychotic depression, plasma cate-
 cholamines, 20:155
race, gender, 22:99
schizophrenia, auditory hallucinations,
 22:99
schizophrenia, β -phenylethylamine,
 21:229
smoking, normals, 20:199
Monoamine oxidase inhibition
 rapid eye movement sleep, 20:177
 social behavior, affective illness, 22:89
 tyramine-pressor response, 22:213
Naloxone
 electroconvulsive therapy, growth
 hormone and prolactin, 22:207
Neuroleptics
 brain distribution, rat, 20:299
 brain and plasma levels, lithium effect,
 20:313
 carbamazepine combined with
 haloperidol, 22:303
 dopamine- β -hydroxylase, dose, 20:221
 β -endorphin, dexamethasone, 21:151
 evoked potentials, lateralized side
 effects, 22:311
 lateralized side effects, evoked potential
 hemispheric asymmetry, 22:311
 life events, relapse, 22:21
 thyroid-stimulating hormone, borderline
 personality disorder, 21:307
Norepinephrine
 affective illness, dexamethasone, 20:143,
 20:155
 cold challenge, affective illness, 21:161
 corticotropin releasing hormone,
 affective illness, 20:229
 cortisol, affective illness, 22:127
 isotope dilution kinetics, 21:313
 lithium distribution, mania, 20:1
Normal values
 adrenal gland volume, CT scan, 21:189
 amino acids, brains, 22:291
 arachidonic acid incorporation, platelet
 membrane phospholipids, 22:275
Normal values (cont.)
 cortisol, dexamethasone, 20:143
 cortisol, plasma, 22:127
 cortisol, plasma, clonidine response,
 20:19
 dexamethasone suppression test, 20:265
 dopamine, plasma, dexamethasone,
 20:143
 electroencephalogram, lithium, 20:117
 β -endorphin, β -lipotropin, plasma,
 21:151
 β -endorphin, plasma, clonidine
 stimulation, 20:19
 epinephrine, dexamethasone, 20:143
growth hormone, clonidine response, 20:19
growth hormone releasing factor,
 cerebrospinal fluid, 22:141
imipramine binding, platelet, 21:33
melatonin, serum and urine, 22:179
3-methoxy-4-hydroxyphenylglycol, plasma,
 22:127
monoamine oxidase, platelets, 20:129,
 22:27, 22:99
norepinephrine, dexamethasone, 20:143
norepinephrine, plasma, 22:127
rauwolscine binding in platelet, 22:43
sleep, EEG frequency analysis, 21:89
smooth pursuit eye movements, 21:293
ventricular size, magnetic resonance
 imaging, 20:33
yohimbine binding, platelet, 20:107
Normetanephrine
 corticotropin-releasing hormone, affective
 illness, 20:229
 lithium distribution, mania, 20:1
Obsessive-compulsive disorder
 birth order, family size 21:347
 imipramine response, 21:123
Opioids
 naloxone, electroconvulsive therapy,
 22:207
Outcome
 emotional blunting, treatment response,
 20:57
 red blood cell/lithium ratio, 20:1
Pain syndromes
 melatonin, neurogenic pain syndrome,
 22:179
Panic disorder
 adolescents, concurrent depressive
 disorders, 20:275
 α_2 -adrenoceptor binding, platelet, 22:43
 adrenocorticotrophic hormone, lactate
 administration, 21:23

Panic disorder (cont.)

- blood pressure, lactate panic, 21:169, 22:263
- catecholamines, cardiovascular measures, 20:13
- CO₂ inhalation, panic provocation, 20:87
- cortisol, lactate effect, 21:23
- epinephrine, anxiety ratings, 21:313
- heart rate, lactate infusion, 22:341
- lactate, blood pressure, 22:263
- lactate infusion, 20:97
- imipramine binding, platelet, 21:33
- 3-methoxy-4-hydroxyphenylglycol, depressed patients, 20:183
- mitral valve prolapse, platelet monoamine oxidase, 20:13
- monoamine oxidase in platelets, 22:37
- norepinephrine kinetics, 21:313
- psychoactive medication, lactate panic, 21:205

Phenylacetic acid

- schizophrenia, monoamine oxidase, 21:229

β -Phenylethylamine

- schizophrenia, monoamine oxidase, 21:229

Phosphate

- affective disorder, serum levels, 22:29

Phospholipids

- arachidonic acid incorporation, platelet membranes, 22:275

Platelets

- adenylate cyclase, lithium, 21:221
- arachidonic acid incorporation, membrane phospholipids, 22:275
- imipramine binding, affective illness, 21:33
- monoamine oxidase, mitral valve prolapse, 20:13
- monoamine oxidase, panic disorder, 22:37
- monoamine oxidase, psychosis proneness, 20:129
- monoamine oxidase, psychotic depression, 20:155
- monoamine oxidase, schizophrenia, 21:229
- rauwolscine binding, panic disorder, 22:43
- serotonin uptake, rat strain differences, 22:61
- yohimbine binding, affective disorder, 20:107

Positron emission tomography

- bipolar and unipolar affective disorder, 22:81

Positron emission tomography (cont.)

- schizophrenia, frontal and parietal lobes, 21:285
- sex differences, glucose, metabolic rate, 21:237

Prolactin

- borderline personality disorder, haloperidol, 21:307
- electroconvulsive therapy and thyroid-stimulating hormone, 20:207
- fenfluramine response, affective disorder, 22:257
- naloxone, electroconvulsive therapy, 22:207
- sleep deprivation, desipramine treatment, 21:337

Race

- schizophrenia, auditory hallucinations, 22:99

Red blood cell

- lithium ratio, monoamine metabolites, 20:1

Rapid eye movement sleep (see Sleep)

Rauwolscine

- panic disorder, platelet binding, 22:43

Reaction time

- cross-over effect, schizophrenia, 22:331

Red blood cell

- sodium transport, lithium effect, 22:49

Scales

- Acute Panic Inventory, lactate infusions, 20:97, 21:169, 21:205
- Beck Depression Inventory, β -adrenoceptor, 20:239
- Beck Depression Inventory, correlation with four self-report scales, 22:243
- Beck Depression Inventory, obsessive-compulsive disorder, 21:123
- Blessed Dementia, Alzheimer's dementia, 21:55
- Blessed Dementia, antidepressant response, 21:111
- Brief Psychiatric Rating Scale, carbamazepine response, 22:303
- Brief Psychiatric Rating Scale, life events, 22:221
- Brief Psychiatric Rating Scale, negative symptoms, 20:47
- Center for Epidemiological Studies—Depression Questionnaire, correlation with four self-report scales, 22:243
- Compulsive Activity Checklist, imipramine response, 21:123
- Emotional Blunting Scale, schizophrenia and affective illness, 20:57
- Folstein Mini-Mental, antidepressants in elderly, 21:111
- Geriatric Depression Scale, hypothyroidism, 21:199

Scales (cont.)

- Hamilton Rating Scale for Anxiety, platelet monoamine oxidase, 22:111
- Hamilton Rating Scale for Depression, adolescent/panic disorder, 20:275
- Hamilton Rating Scale for Depression, α_2 -adrenoceptor affinity, 20:107
- Hamilton Rating Scale for Depression, β -adrenoceptor binding, 20:239
- Hamilton Rating Scale for Depression, cerebrospinal fluid amine metabolites, 21:1
- Hamilton Rating Scale for Depression, electroconvulsive therapy, 20:207
- Hamilton Rating Scale for Depression, light treatment, 22:1
- Hamilton Rating Scale for Depression, monoamine oxidase 20:155
- Hamilton Rating Scale for Depression, phosphate and calcium, 22:29
- Hamilton Rating Scale for Depression, rapid eye movement sleep, 20:189
- Hamilton Rating Scale for Depression, sleep deprivation, 21:95
- Hamilton Rating Scale for Depression, thyroid-stimulating hormone, 22:21
- Inpatient Multidimensional Rating Scale, carbamazepine response, 22:303
- Manic Diagnostic and Severity Scale, lithium, 20:1
- Maudsley Obsessional-Compulsive Inventory, 21:123
- Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
- Minnesota Multiphasic Personality Inventory, serum phosphate, 22:29
- Minnesota Multiphasic Personality Inventory D Scale, correlation with four self-report scales, 22:243
- Montgomery-Asberg Depression Scale, platelet monoamine oxidase, 22:111
- Perceptual Aberration Scale, platelet monoamine oxidase, 20:129
- Physical Anhedonia Scale, platelet monoamine oxidase, 20:129
- Plutchik-van Praag Self-Report Depression Scale, criteria for depression, 22:293
- Profile of Mood States, sleep deprivation, 21:95
- Scale for Assessment of Negative Symptoms, redundant measures, 20:47

Scales (cont.)

- Spielberger Anxiety Rating, bulimia, 21:213
- Spielberger Anxiety Rating, imipramine response, 21:123
- Spielberger Anxiety Rating, plasma caffeine, 21:247
- Stanford Sleepiness Scale, sleep deprivation, 22:149
- Subjective Units of Disturbance, anxiety, 20:87
- Wechsler Adult Intelligence Scale, ventricular enlargement, 21:137
- Wechsler Rating Scale for Depression, 20:19
- Zung Depression Scale, anorexia nervosa, 20:19
- Zung Depression Scale, comparison with four self-report scales, 22:243
- Zung Anxiety Rating, plasma caffeine, 21:247
- Schizophrenia**
- β -adrenoceptor binding, dexamethasone suppression test, 22:265
- affect in facial emotion, photo judgment, 20:317
- amino acids, cerebrospinal fluid, 20:337
- amino acids, post-mortem brain, 22:291
- γ -aminobutyric acid (GABA), post-mortem brain, 22:291
- amphetamine induction of psychosis, 5-hydroxytryptophan, 22:283
- auditory hallucinations, platelet-monoamine oxidase, 22:99
- blood-brain barrier permeability, dynamic computed tomography, 22:229
- blood pressure, speaking, 22:69
- carbamazepine, clinical response, 22:303
- computed tomography, blood-brain barrier permeability, 22:229
- computed tomography, contrast material time density curves, 20:165
- computed tomography, methodology, 22:91
- contingent negative variation, reaction time, 22:331
- cross-over effect, evoked potentials, 22:331
- deficit syndrome, neuropsychological impairment, 22:319
- dexamethasone suppression test, β -adrenoceptor binding, 22:265
- dopamine- β -hydroxylase, family studies, 20:221
- educational level, deficit syndrome, 22:319
- electroconvulsive therapy, thyroid-stimulating hormone, 20:207

Schizophrenia (cont.)

- electroencephalogram, ventricular enlargement, 21:137
- emotional blunting, factor analytic study, 20:57
- employment status, blood pressure, 22:69
- evoked potentials, hemispheric asymmetry, 22:311
- evoked potentials, reaction time, 22:331
- eye movements, lateralization, 20:215
- eye movements, ventricle size, 21:293
- facial emotion judgments, 20:317
- fibroblasts, growth and response to toxic oxygen metabolites, 21:43
- frontal lobe, blood-brain barrier permeability, 22:229
- frontal white matter, magnetic resonance image, 20:33
- hallucinations, platelet monoamine oxidase, 22:99
- head trauma history, 21:303
- heart rate, speaking, 22:69
- high risk sample, Minnesota Multiphasic Personality Inventory, 22:159
- human leukocyte antigens, chromosome 6, 20:69
- 5-hydroxytryptophan, amphetamine induction of psychosis, 22:283
- hypofrontality, dynamic computed tomography, 22:229
- hypofrontality, positron emission tomography, 21:285
- laterality, blood-brain barrier permeability, 22:229
- laterality, clockwise circling, 20:215
- lateralized neuroleptic side effects, evoked potentials, 22:311
- life events, relapse, 22:221
- Luria-Nebraska Neuropsychological Battery, ventricular enlargement, 21:137
- magnetic resonance imaging, image intensity, 20:33
- Minnesota Multiphasic Personality Inventory, diagnosis, 22:159
- monoamine oxidase in platelet, auditory hallucinations, 22:99
- monoamine oxidase in platelets, psychosis proneness, 20:129
- monoamine oxidase, urinary phenylethylamine, 21:229
- negative symptoms, neuropsychological impairment, 22:319
- negative symptom measurement, 20:47
- negative symptoms, ventricular enlargement, 21:137

Schizophrenia (cont.)

- neuroleptics, relapse and life events, 22:221
- neuropsychological impairment, deficit syndrome, 22:319
- paranoid type, phenylethylamine in urine, 21:229
- paranoid type, platelet monoamine oxidase, 22:99
- phenylacetic acid, platelet monoamine oxidase, 21:229
- phenylethylamine, platelet monoamine oxidase, 21:229
- positron emission tomography, 21:285
- prolactin, electroconvulsive therapy, 20:207
- race, platelet monoamine oxidase, 22:99
- reaction time cross-over effect, evoked potentials, 22:331
- relapse, life events, 22:221
- schizoaffective disorder diagnosis, high-risk sample, 22:159
- schizophreniform, arachidonic acid incorporation, 22:275
- serotonin, psychosis induction by amphetamine, 22:283
- sex differences, platelet monoamine oxidase, 22:99
- speaking, cardiovascular response, 22:69
- ventricular enlargement, smooth pursuit eye movements, 21:293
- ventricular enlargement, Wechsler Adult Intelligence Scale, 21:137
- ventricular size, 20:33, 21:49
- ventricular size, methodological review, 22:91
- tardive dyskinesia, evoked potentials, 22:311
- Seasonal affective disorder
- light treatment, mood change in normals, 22:1
- Serotonin
- amphetamine induced psychosis, 5-hydroxytryptophan, 22:283
- platelet uptake, methods and rat-strain differences, 22:61
- prolactin response to fenfluramine, affective disorder, 22:257
- Sex differences
- dopamine- β -hydroxylase, schizophrenia, 20:221
- lactate response, panic disorder, 22:341
- glucose metabolic rate, positron emission tomography, 21:237
- melatonin, chronic pain, 22:179
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 20:13

Sex differences (cont.)

- monoamine oxidase in plasma, panic disorder, 20:13
- monoamine oxidase in platelets, panic disorder, 20:13
- monoamine oxidase, platelets, 20:129, 20:155, 20:199, 22:37, 22:99
- panic disorder, lactate response, 22:341

Sleep

- arecoline infusion, rapid eye movement sleep, 22:261
- carbamazepine response, 21:71, 22:11
- deprivation, carbamazepine effect, 22:11
- deprivation, desipramine effect, 21:337
- frequency analysis, affective illness, 21:89
- growth hormone, sleep deprivation, 21:337
- monoamine oxidase inhibition, rapid eye movements, 20:177
- phase shift, mood change in normals, 22:149
- prolactin, sleep deprivation, 21:337
- rapid eye movement sleep, acute sleep delay, 22:149
- sleep deprivation, endogenous depression, 21:95

Sodium transport

- lithium effect, bipolar affective disorder, 22:49

Substance abuse

- cocaine craving, bromocriptine, 20:261
- monoamine oxidase, perceptual aberration, 20:129
- paraphernalia, cocaine, 20:261

Tachycardia (see Heart rate)

Tardive dyskinesia

- lateralized neuroleptic side effects, evoked potentials, 22:311

Thyroid-stimulating hormone

- β -adrenoceptor binding, dexamethasone suppression, 20:239

Thyroid-stimulating hormone (cont.)

- catecholamines, affective illness, 22:127
- depressive symptoms, nursing home, 21:199
- 3-methoxy-4-hydroxyphenylglycol, affective illness, 22:21
- neuroleptic effect, borderline personality disorder, 21:307
- prolactin and electroconvulsive therapy, 20:207

Triiodothyronine

- antidepressant potentiation, rat learned helplessness, 21:267
- borderline personality disorder, neuroleptic effect, 21:307

Tyramine pressor response

- monoamine oxidase inhibitor, moclobemide, 22:213

Vanillylmandelic acid

- corticotropin-releasing hormone, affective illness, 20:229

Ventricular size

- computed tomographic measurement, 22:91
- negative symptoms, neuropsychological scores, 21:137
- schizophrenia, magnetic resonance imaging, 20:33
- schizophrenia, third ventricle, 21:49
- smooth pursuit eye movements, schizophrenia, 21:293

Weight

- anorexia nervosa, desmethyl-imipramine, 20:19
- clonidine, anorexia nervosa, 20:249
- growth hormone-releasing factor, cerebrospinal fluid, 22:141

Yohimbine

- affective disorder, platelet binding, 20:107